Axsome Therapeutics, Inc. (AXSM) shares tumbled 5.8% to $156.32 as of October 14, 2026, a significant decline from the prior close of $166.00. BestStocks flagged the session as a major change for AXSM. Below, we break down what changed for AXSM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
AXSM fell 5.8% to $156.32
Axsome Therapeutics fell 4.7% on August 20, 2026, as investors digested the company's Q2 earnings report, which revealed a net loss of $51.3 million despite strong revenue growth of $218.4 million driven by its flagship product Auvelity. The decline reflects concern over elevated operating expenses tied to commercialization efforts and delayed near-term profitability, compounded by broader risk-off sentiment in mid-cap biotech equities amid a high-interest-rate environment.
What it means for Axsome Therapeutics, Inc. investors
For Axsome Therapeutics, Inc. investors, the recent signals add up to a strong bearish shift. On the constructive side: Positive price momentum; Axsome Therapeutics, Inc. (AXSM) moved +6.91% from $221.64 to $236.95 on 2026-07-21. Weighing against that: Material negative event; Sharp 5.8% decline — elevated risk. Wall Street's consensus price target sits at $283.00, implying +81.0% upside from $156.32. BestStocks rates the overall signal quality medium (63/100). With earnings roughly 19 days out, the next report is the most likely near-term test of the move.
AXSM price reaction
AXSM last traded at $156.32, down $9.68 (-5.83%) from the previous close of $166.00. The session traded on 1.6× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $156.32 and $216.58, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Axsome Therapeutics, Inc. (AXSM)
The consensus analyst price target on Axsome Therapeutics, Inc. (AXSM) is $283.00, 81.0% above the recent $156.32. Over the past 90 days analysts logged 0 upgrades, 13 maintains, and 0 downgrades. Here is how the bullish and bearish cases on AXSM line up.
▲ The bullish case
+Wall Street's consensus price target of $283.00 implies +81.0% upside from $156.32.
+The Street's most bullish target is $380.00 (+143.1%).
+Positive price momentum.
+Axsome Therapeutics, Inc. (AXSM) moved +6.91% from $221.64 to $236.95 on 2026-07-21.
▼ The bearish case
−Material negative event.
−Sharp 5.8% decline — elevated risk.
−Axsome Therapeutics, Inc. moved -3.74% intraday from $203.10 to $195.50.
Bull vs bear balanceStrong Bearish Shift
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 14, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Axsome projects $8 billion peak Auvelity sales with expansion into Alzheimer's disease indication.
Material / Earnings2026-10-12-1.4%
Axsome Therapeutics, Inc. (AXSM) moved -2.01% from $169.41 to $166.00 on 2026-10-12. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. The move coincided with AXSM reaching a new 30-day low; volume remained near its 5-day average.
News2026-10-07-0.8%
Axsome scheduled Q3 2026 earnings release for November 2.
Axsome Therapeutics, Inc. moved -3.60% intraday from $193.89 to $186.91. Axsome Therapeutics (AXSM ) moved slightly lower in regular trading on September 29, 2026, dropping around 3% amid minor routine profit-taking and broader market crosscurrents rather than any negative company-specific catalysts. ### 💡 Market Context & Fundamentals - 📉 Routine Pullback: The modest dip follows a strong multi-month run and heavy institutional accumulation, pointing to standard consolidation. - 📈 Positive Momentum: Fundamental updates remain highly constructive, highlighted by accelerating commercial prescription growth for Auvelity and strong presentation traction at recent medical meetings like Psych Congress. - 🔎 Analyst Support: Wall Street sentiment remains bullish, underscored by recent target hikes (such as Truist raising its target to $285) alongside ongoing "Buy" and "Overweight" ratings across major firms. To give you more specific financial or portfolio context, are you looking at AXSM from a short-term trading perspective or a long-term investment horizon?
Axsome Therapeutics, Inc. moved -3.74% intraday from $203.10 to $195.50. Axsome Therapeutics (AXSM ) is seeing a mild pullback amid ongoing profit-taking following its recent multi-year run and investor digestion of high cash burn against commercial growth. ### 📊 Market Context & Drivers - 💡 No Negative Catalyst: There are no adverse regulatory announcements or clinical trial failures driving the dip. - 📈 Recent Run-Up: Investors are locking in gains after recent presentations at the H.C. Wainwright and Psych Congress 2026 conferences. - ⚠️ Financial Burn: The market continues to weigh strong prescription trends for Auvelity against ongoing corporate losses and high operating expenses. If you'd like, let me know: - Your investment timeline (short-term trade or long-term hold) - Whether you are tracking specific pipeline catalysts (like upcoming trial readouts) I can provide a more tailored look at Axsome's valuation and risk profile.
Material / Earnings2026-09-16+3.9%
Axsome Therapeutics, Inc. (AXSM) moved +4.16% from $203.50 to $211.97 on 2026-09-16. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, suggesting the move occurred without elevated trading activity.
Material / Earnings2026-09-15-5.8%
Axsome Therapeutics, Inc. (AXSM) moved -5.09% from $215.02 to $204.07 on 2026-09-15. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average, suggesting the decline was not driven by unusual trading activity.
Axsome Therapeutics gained 7.71% to $227.39 following a presentation at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 10 (Seeking Alpha). The company, now operating as a commercial-stage entity with growing revenue from CNS treatments, appears to have reinforced investor confidence in its revenue trajectory and commercial execution during the investor event.
In-depth AXSM event analyses
Permanent, dated analyses of AXSM's most significant sessions.
Why did Axsome Therapeutics, Inc. (AXSM) stock move?
Axsome Therapeutics fell 4.7% on August 20, 2026, as investors digested the company's Q2 earnings report, which revealed a net loss of $51.3 million despite strong revenue growth of $218.4 million driven by its flagship product Auvelity. The decline reflects concern over elevated operating expenses tied to commercialization efforts and delayed near-term profitability, compounded by broader risk-off sentiment in mid-cap biotech equities amid a high-interest-rate environment.
How much did AXSM stock fall?
AXSM lost 5.83% ($9.68) versus the prior close of $166.00, last trading at $156.32 on 1.6× average volume.
When is Axsome Therapeutics, Inc.'s next earnings date?
AXSM's next earnings report is estimated for 2026-11-02 — about 19 days away.
What is the analyst price target for AXSM?
The consensus analyst price target for AXSM is $283.00, about 81.0% above the current $156.32. Over the past 90 days, analysts recorded 0 upgrades, 13 maintains, and 0 downgrades.
How BestStocks tracks AXSM
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared AXSM-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for AXSM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 14, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
